Clinical pharmacokinetics of antiretroviral drugs in older persons

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 5, 2013, Pages 573-588

  Schoen, John C ^a   Erlandson, Kristine M ^b   Anderson, Peter L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Clinical pharmacology; Elderly; HIV; Pharmacokinetics

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

AGING; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ELIMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLASMA PROTEIN BINDING; REVIEW; VIRUS HEPATITIS;

ADULT; AGED; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GUIDELINES AS TOPIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY; LAMIVUDINE; LIVER; LOPINAVIR; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; YOUNG ADULT;

EID: 84876367123     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.781153     Document Type: Review

References (145)

1. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47:542-53
2. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010;7:69-76
3. Centers for Disease Control and Prevention (CDC). HIV surveillance-United States, 1981 - 2008. MMWR Morb Mortal Wkly Rep 2011;60:689-93
4. Institute of Medicine (US) Committee on Pharmacokinetics and Drug Interactions in the Elderly. Pharmacokinetics and drug interactions in the elderly and special issues in elderly African-American populations: workshop summary. 1997 The national academies collection: reports funded by national institutes of health. Available from: http://www.nap.edu/catalog/5854.html [Accessed 02 January 2013]
5. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53:1120-6
6. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol Ser A 2007;62:1279-86
7. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for industry, studies in support of special populations: geriatrics. 1994. Available from: http://www.fda.gov/ downloads/RegulatoryInformation/ Guidances/UCM129519.pdf [Accessed 02 January 2013]
8. Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 2013;26:17-25
9. Rhee M. Greenblatt, DJ. Pharmacologic consideration for the use of antriretroviral agents in the elderly. J Clin Pharmacol 2008;48:1212-25 1
10. Branas F, Berenguer J, Sanchez-Conde M, et al. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med 2008;121:820-4 1
11. Negin J, Cumming RG. HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ 2010;88:847-53 1
12. Hontelez JA, Lurie MN, Newell ML, et al. Ageing with HIV in South Africa. AIDS 2011;25:1665-7 1
13. Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med 2007;23:567-83 1
14. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67-76 1
15. Onen N, Overton E, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010;11:100-9 1
16. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV Cohort study. Clin Infect Dis 2011;53:1130-9 1
17. Bhavan KP, Kampalath VN, Overton ET. The aging of the HIV epidemic. Curr HIV/AIDS Rep 2008;5:150-8 1
18. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56 1
19. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Updated March 27, 2012. Available from: http://www.aidsinfo.nih. gov/contentfiles/lvguidelines/ adultandadolescentgl. pdf [Accessed 02 January 2013] 2
20. Liptrott NJ, Pushpakom S, Wyen C, et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics 2012;22:10-19 . Example of emerging information on drug transporters and ARV PK. 2
21. Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S, et al. Genetic variants of ABCC10, a Novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011;204:145-53 2
22. Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: an overview. Adv Drug Deliv Rev 2012 [Epub ahead of print] 2
23. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011;66:2107-11 2
24. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A504. AIDS 2002;16:569-77 2
25. Levitra- (vardenafil) product information. 2012 GlaxoSmithKline. Research Triangle, Park, NC 2
26. Cusack B. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004;2:274-302 2
27. Knox TA, Oleson L, von Moltke LL, et al. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008;49:358-68 2
28. Kharasch ED, Whittington D, Ensign D, et al. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2012;91:673-84 2
29. Svärd J, Spiers JP, Mulcahy F, Hennessy M. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and Sub-Saharan Africans. J Acquir Immune Defic Syndr 2010;55:536-49 3
30. Tang C, Lin JH, Lu AY. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab Dispos 2005;33:603-13 3
31. Ngaimisi E, Mugusi S, Minzi OM, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010;88:676-84 3
32. Anderson PL, Aquilante CL, Gardner EM, et al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother 2009;64:1071-9 3
33. Josephson F, Allqvist A, Janabi M, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007;81:708-12 3
34. Anderson PL, Lamba J, Aquilante CL, et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006;42:441-9 3
35. Savic RM, Barrail-Tran A, Duval X, et al. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther 2012;92:575-83 3
36. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005;15:1-5 3
37. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008;61:914-18 3
38. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005;192:1381-6 3
39. Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of Raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther 2009;85:623-7 4
40. Haas D, Kuritzkes D, Ritchie M, et al. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the national institute of allergy and infectious diseases. HIV Clin Trials 2011;12:277-85 4
41. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008;47:297-321 4
42. Mayersohn M. Special pharmacokinetic considerations in the elderly. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd edition. Applied Therapetuics, Inc; Vancouver, WA: 1992 4
43. Hilmer SN. ADME-tox issues for the elderly. Expert Opin Drug Metab Toxicol 2008;4:1321-31 4
44. Blanco JR, Caro AM, Perez-Cachafeiro S, et al. HIV infection and aging. AIDS Rev 2010;12:218-30 4
45. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008;47:75-89 4
46. Morley JE. Undernutrition in older adults. Fam Pract 2012;29:i89-93 4
47. Bauer M, Karch R, Neumann F, et al. Age dependency of cerebral P-gp function measured with (R)-[11C] verapamil and PET. Eur J Clin Pharmacol 2009;65:941-6 4
48. Toornvliet R, van Berckel BN, Luurtsema G, et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006;79:540-8 4
49. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011;8:54-61 5
50. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Wolters Kluwer Health, Lippincott, Williams and Wilkins; Baltimore MD: 198
51. Bach B, Hansen JM, Kampmann JP, et al. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981;6:389-96 5
52. Rodriguez CE, Mahle DA, Gearhart JM, et al. Predicting age-appropriate Pharmacokinetics of six volatile organic compounds in the rat utilizing physiologically based pharmacokinetic modeling. Toxicol Sci 2007;98:43-56 5
53. Sotaniemi E, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans; an analysis of 226 subjects with equal histopathic conditions. Clin Pharmacol Ther 1997;61:331-9 5
54. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60 5
55. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35:876-84 5
56. Dorne JL, Walton K, Renwick AG. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem Toxicol 2001;39:1153-73 5
57. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010;85:190-200 5
58. Helou R. Should we continue to use the Cockcroft-Gault formula? Nephron Clin Pract 2010;116:c172-85 5
59. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595-612 6
60. Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs 2005;65:1427-48 6
61. O'mara E, Randall D, Stoltz RR, et al. BMS-232632: a prospective study of age and gender effects on the single-dose pharmacokinetics in healthy volunteers [abstract 350]. 1st IAS Conference on HIV Pathogenesis and Treatment; 7 - 11 July 2001; Buenos Aires, Argentina 6
62. Crawford KW, Spritzler J, Kalayjian RC, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010;26:635-43 6
63. Merle P, Trepo C, Zoulim F. Current management strategies for hepatitis B in the elderly. Drugs Aging 2001;18:725-35 6
64. Mukonzo JK, Nanzigu S, Rekic D, et al. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet 2011;50:531-40 6
65. Chan PL, Weatherley B, McFadyen L. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol 2008;65(Suppl 1):76-85 6
66. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009;85:485-94 6
67. Schipani A, Egan D, Dickinson L, et al. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir Ther 2012;17:861-8 6
68. Bazzoli C, Benech H, Rey E, et al. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. Antimicrob Agents Chemother 2011;55:3423-31 6
69. Kityo C, Walker AS, Dickinson L, et al. Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Antimicrob Agents Chemother 2010;54:2965-73 7
70. Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reversetranscriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther 2010;88:695-703 7
71. Kwara A, Lartey M, Sagoe KW, et al. CYP2B6 (c.516GT) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009;67:427-36 7
72. Schipani A, Siccardi M, D'Avolio A, et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010;54:5242-50 7
73. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, et al. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother 2012;56:2959-66 7
74. Smith PF, Dicenzo R, Forrest A, et al. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clin Pharmacokinet 2005;44:99-109 7
75. Sanchez A, Cabrera S, Santos D, et al. Population pharmacokinetic/ pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother 2011;55:5314-24 7
76. Kappelhoff BS, Huitema AD, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005;44:849-61 7
77. von Hentig N, Lotsch J. Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009;53:3524-7 7
78. Lopez Aspiroz E, Santos Buelga D, Cabrera Figueroa S, et al. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients. Ther Drug Monit 2011;33:573-82 7
79. Baheti G, Kiser JJ, Havens PL, Fletcher CV. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother 2011;55:5294-9 8
80. Benaboud S, Hirt D, Launay O, et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother 2012;56:857-62 8
81. Panhard X, Legrand M, Taburet AM, et al. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur J Clin Pharmacol 2007;63:1019-29 8
82. Schipani A, Wyen C, Mahungu T, et al. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother 2011;66:1332-9 8
83. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010;20:217-30 8
84. Cressey TR, Urien S, Hirt D, et al. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir. Ther Drug Monit 2011;33:25-31 8
85. Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008;84:75-82 8
86. Molto J, Valle M, Miranda C, et al. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. J Antimicrob Chemother 2008;62:784-92 8
87. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995;39:2309-15 8
88. Panhard X, Goujard C, Legrand M, et al. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Br J Clin Pharmacol 2005;60:390-403 8
89. Kappelhoff BS, Huitema AD, Sankatsing SU, et al. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005;60:276-86 9
90. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010;20:112-20 9
91. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008;13:675-85 9
92. Goujard C, Legrand M, Panhard X, et al. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. Clin Pharmacokinet 2005;44:1267-78 9
93. Chou M, Bertrand J, Segeral O, et al. Population pharmacokinetic- pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010;54:4432-9 9
94. Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997;41:2428-32 9
95. Kappelhoff BS, Huitema AD, Crommentuyn KM, et al. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol 2005;59:174-82 9
96. Crommentuyn KM, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005;60:378-89 9
97. Elsherbiny D, Cohen K, Jansson B, et al. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009;65:71-80 9
98. Gandhi M, Benet LZ, Bacchetti P, et al. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009;50:482-91 9
99. Solas C, Gagnieu MC, Ravaux I, et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit 2008;30:670-3 10
100. Bertrand J, Treluyer JM, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol 2009;65:667-78 10
101. Siccardi M, D'Avolio A, Nozza S, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet Genomics 2010;20:759-65 10
102. Stohr W, Back D, Dunn D, et al. Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother 2010;65:129-37 10
103. Dailly E, Billaud E, Reliquet V, et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004;60:343-8 10
104. Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000;14:2869-76 10
105. Van Der Leur MR, Burger DM, La Porte CJL, Koopmans PP. A retrospective TDM database analysis ofinterpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit 2006;28:650-3 10
106. Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012;68:689-95 10
107. Gagnieu MC, Barkil ME, Livrozet JM, et al. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol 2008;48:1282-8 10
108. Okoli C, Siccardi M, Thomas-William S, et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother 2012;67:671-4 10
109. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002;46:746-54 11
110. Adams JM, Shelton MJ, Hewitt RG, et al. Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother 1998;42:821-6 11
111. Zhou XJ, Sheiner LB, D'Aquila RT, et al. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999;43:121-8 11
112. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003;73:20-30 11
113. Heil SG, van der Ende ME, Schenk PW, et al. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit 2012;34:153-9 11
114. Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med 2010;11:326-33 11
115. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006;50:3801-8 11
116. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006;61:148-54 11
117. Jullien V, Treluyer JM, Rey E, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 2005;49:3361-6 11
118. Pfister M, Labbe L, Lu JF, et al. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther 2002;72:133-41 11
119. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 2004;48:3226-32 12
120. Siccardi M, D'Avolio A, Rodriguez-Novoa S, et al. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit 2012;34:232-5 12
121. von Hentig N, Babacan E, Lennemann T, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008;62:579-82 12
122. Barrail-Tran A, Mentre F, Cosson C, et al. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents Chemother 2010;54:614-19 12
123. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005;40:1358-61 12
124. Dailly E, Raffi F, Perre P, et al. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach. HIV Med 2009;10:586-9 12
125. Jackson KA, Rosenbaum SE, Kerr BM, et al. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2000;44:1832-7 12
126. Moore KH, Yuen GJ, Hussey EK, et al. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 1999;43:3025-9 12
127. de Maat MM, Huitema AD, Mulder JW, et al. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002;54:378-85 12
128. Mould DR, Zhang X, Nieforth K, et al. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2005;77:515-28 12
129. Custodio J, Gordi T, Chang S, et al. Population pharmacokinetics of Cobicistat-boosted Elvitegravir in adult healthy subjects and HIV-infected patients (paper P-O2). 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16 - 18 April 2012; Barcelona, Spain 13
130. Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of Darunavir and Etravirine in HIV-1- Infected, treatment-experienced patients in the Gender, Race, and Clinical Experience (GRACE) trial. AIDS Res Treat 2012;2012:186987 13
131. Crauwels H, Van Schaik R, Van Heeswijk RP, et al. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-nave, HIV-1-infected patients in ECHO and THRIVE (paper P186). 10th International Congress on Drug Therapy in HIV Infection; 7 - 11 November 2010; Glasgow, UK 13
132. Kile DA, Mawhinney S, Aquilante CL, et al. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses 2012;28(10):1227-34 13
133. Molto J, Valle M, Xinarianos G, et al. Simultaneous pharmacogenetics- based population pharmacokinetic analysis of darunavir and ritonavir in HIV+ individuals (paper 623). 19th Conference on Retroviruses and Opportunistic Infections; 5 - 8 March 2012; Seattle, WA 13
134. Dickinson L, Jackson A, Garvey L, et al. Population pharmacokinetic modelling of once daily Ritonavir-boosted Darunavir in HIV-infected Patients (paper P184). J Int AIDS Soc 2010;13(Suppl 4):P184 13
135. Weller S, Radomski KM, Lou Y, Stein DS. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2000;44:2052-60 13
136. Jullien V, Treluyer JM, Chappuy H, et al. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br J Clin Pharmacol 2005;59:183-8 13
137. Brendel K, Legrand M, Taburet AM, et al. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. Fundam Clin Pharmacol 2005;19:373-83 13
138. King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006;45:665-82 13
139. Dailly E, Raffi F, Biron C, et al. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. Fundam Clin Pharmacol 2008;22:101-4 14
140. Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007;167:684-91 14
141. Nachega JB, Hsu AJ, Uthman OA, et al. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012;26:S39-53 14
142. Silverberg MJ, Jacobson LP, French AL, et al. Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy. J Pain Symptom Manage 2009;38:197-207 14
143. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 200. Arch Intern Med 2010;170:57-65 14
144. American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31 14
145. Schaeffner ES, Ebert N, Delanaye P, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012;157:471-81